In contrast to the systemic or intrathecal administration required for non-ocular diseases, a local intravitreal administration for retinal diseases, such as LCA10, has fundamental advantages because only relatively small doses of intrinsically long-acting AONs are required. The gene discussed is CEP290; the disease is Abnormal retinal morphology.